Bactiguard Holding AB (publ) (BACTI-B)
Stockholm Exchange · Sweden · prices in SEK · close of 19 Oct 2026
Key indicators
| Last close | SEK 15.45 |
|---|---|
| 52-week range | 13.60 – 21.60 |
| Return, 1 month / 3 months | −0.6% / −3.1% |
| Return, 1 year / 3 years | −16.3% / −74.1% |
| Trend | Below its 200-day average |
| RSI (14) | 47 |
| Volatility (1 year) | 59.0% |
| Worst drawdown (1 year) | -29.1% |
| Average daily value traded | 0.10M SEK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Bactiguard Holding AB develops and supplies infection-prevention technology for medical devices. Its coating, based on noble metals, is applied to products such as urinary catheters and orthopaedic implants to reduce the risk of bacterial infection. The company works with medical device manufacturers that license the technology, and it also provides its own coated products to healthcare providers. Bactiguard is based in Stockholm, Sweden, and serves customers in healthcare and medical technology markets internationally.
The shares are listed on the Stockholm Exchange in Sweden under the code BACTI-B, and the price on this page is in Swedish kronor (SEK). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Bactiguard Holding AB (publ) (BACTI-B) trades on the Stockholm Exchange in Sweden. It last closed at SEK 15.45 on 19 October 2026.
Its price-based Market X-Ray is 47 out of 100 (a weak price profile), ranking 511 of 911 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 16.3% and over the last three months it fell 3.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Stockholm Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 52 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -5.3% | ||
| From 52-week high | -22.4% | ||
| Momentum | 45 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -3.1% | ||
| 6-month return | -12.5% | ||
| 12-month return, skipping the last month | -15.7% | ||
| Stability (higher is calmer) | 55 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 59.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -29.1% | ||
| Liquidity | 29 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.10M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Momentum: Lagging most stocks on this exchange.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −3.4% |
|---|---|
| 1 month | −0.6% |
| 3 months | −3.1% |
| 6 months | −12.5% |
| 1 year | −16.3% |
| 3 years | −74.1% |
| 5 years | – |
Signals
| 50-day / 200-day average | 15.76 / 16.32 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.81 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Stockholm Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.